Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 178

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 178
---
 with the U.S. Food and Drug Administration (“FDA”) in the coming 12 to 24 months, starting with PTK7-CPT113 for the treatment of solid tumors, including non-smallcell lung cancer (“NSCLC”) and ovarian cancer, in the second half of 2025; mMUC16-CPT113 for the treatment of cancers of female origin by the end of 2025; and biSEZ6-CPT113 for the treatment of cancers of neuroendocrine origin in mid-2026.With these three assets, we have the ability to pursue multiple cancer indications with high potential in large addressable patient populations, including and beyond those indications currently expected to be targeted in the upcoming Phase 1 trials. Our track record of strong execution of novel drug formulation, research, clinical development, and commercialization in precision oncology, combined with our deep understanding of ADCs positions us to unlock the high potential of this differentiated ADC portfolio. Our management team has extensive experience in the discovery, development, and commercialization of cancer therapeutics, including in senior roles at leading oncology companies. We are supported by our board of directors and specialized scientific advisors, who contribute their deep understanding of drug discovery and development. Furthermore, our investor base includes top life science investors. We believe that our team is well positioned to execute on our strategy to develop and, if approved, commercialize these three ADCs and future pipeline assets to ultimately bring broad benefit to cancer patients worldwide. Our Strategy Our vision is to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treatcancers. The principal components of our strategy include:

| • |     | We leverage “next wave” ADC architecture. Recently, next wave ADCs have been associated                                                                                                                                                    
 with double-digit improvement in objective response rates (“ORR”) over first generation ADCs against the same target across a variety of solid tumors, including ovarian, breast cancer, and lung cancers. Next wave ADC architectures are 
 typified by improved linker-antibody stability, optimized                                                                                                                                                                                  |

- 116 -

| pharmacokinetics and improved inhibitor payloads, such as using TOPO1 in lieu of monomethyl auristatin E (“MMAE”). |

| • |     | We preferentially pursue clinically validated targets and identify opportunities for                                                                                                                                                               
 differentiation. Rather than expend resources on target discovery, we leverage our team’s deep experience in oncology and biologics, review existing oncology target literature and engage with key opinion leaders to